Although continuous BTK inhibitors have the most prospective data for high-risk CLL (17p/TP53 mutations), some highly motivated patients still opt for fixed-duration treatment. This requires a detailed conversation where clinicians must explain the trade-off: achieving a treatment-free period may come at the cost of needing second-line therapy sooner.

Platelet aggregation studies show riluzobrutinib does not impair platelet function. This unique profile suggests it may not need to be stopped before surgery, avoiding the risk of a perilous drop in platelet counts for ITP patients—a key differentiator from other BTK inhibitors.

When starting a BTK inhibitor for CLL, patients often experience a sharp increase in their lymphocyte count. This is not a sign of disease progression but a therapeutic effect as the drug forces malignant cells out of the lymph nodes. This effect typically normalizes over 6-8 weeks and should be explained to patients.

In CLL, Progression-Free Survival (PFS) is a misleading metric for clinical benefit. Time-To-Next-Treatment (TTNT) is often much longer because patients can have biochemical or radiological progression by IWCLL criteria but remain asymptomatic and clinically well, delaying the need for a new therapy.

Improved T-cell function in CLL patients on BTK inhibitors is probably a result of the substantial reduction in disease burden, allowing the immune system to normalize. This effect is seen across different BTK inhibitors, challenging the older hypothesis that it was a specific off-target effect (ITK inhibition) of ibrutinib.

If a patient's CLL therapy is stopped for another major health issue, such as a second cancer, clinicians should often observe them post-recovery rather than immediately restarting treatment. This approach is recommended even with detectable Minimal Residual Disease (MRD) to prioritize the patient's immune system recovery and overall health.

While the continuous BTK inhibitor zanubrutinib showed longer progression-free survival, this efficacy came with a significant safety trade-off. It led to a 47% rate of serious adverse events compared to 24% for the fixed-duration acalabrutinib-venetoclax combination in the indirect analysis.

For older CLL patients, stopping acalabrutinib after 18 months results in relapse within a year for half of them. However, their overall survival remains identical to those who continue treatment, suggesting a "drug holiday" is a safe option for managing side effects or patient preference without long-term detriment.

BTK inhibitors block B-cell receptor signaling, causing long-surviving CLL cells to undergo programmed cell death (apoptosis) from a lack of stimulation. The common side effects are due to off-target kinase inhibition, not the intended BTK blockade itself, which has negligible action on other cells.